EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Efficacy And Safety Evaluation of AAV‐ OTOF in DFNB9 Mouse Model And Nonhuman Primate

Jieyu Qi, Liyan Zhang, Fangzhi Tan, Yang Zhang, Yinyi Zhou, Ziyu Zhang, Hongyang Wang, Chaorong Yu, Lulu Jiang, Jiancheng Liu, Tian Chen, Lianqiu Wu und 6 weitere

Advanced Science · 2024-01 · 11 (3)

DOI: 10.1002/advs.202306201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 28.11.2023. Verfasst von Jieyu Qi und 17 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Digital Medical Engineering, Department of Otolaryngology Head and Neck Surgery, Zhongda Hospital, School of Life Sciences an…. Hauptthemen laut MEDLINE: Hearing Loss, Sensorineural, Hearing Loss. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, STI2030-Major Projects, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OTOF mutations are the principal causes of auditory neuropathy. There are reports on Otof ‐related gene therapy in mice, but there is no preclinical research on the drug evaluations. Here, Anc80L65 and the mouse hair cell‐specific Myo15 promoter (mMyo15) are used to selectively and effectively deliver human OTOF to hair cells in mice and nonhuman primates to evaluate the efficacy and safety of OTOF gene therapy drugs. A new dual‐AAV ‐OTOF‐ hybrid strategy to transfer full‐length OTOF is generated, which can stably restore hearing in adult OTOF p.Q939*/Q939* mice with profound deafness, with the longest duration being at least 150 days, and the best therapeutic effect without difference in hearing from wild‐type mice. An AAV microinjection method into the cochlea of cynomolgus monkeys without hearing impairment is further established and found the OTOF can be safely and effectively driven by the mMyo15 promoter in hair cells. In addition, the therapeutic dose of AAV drugs has no impact on normal hearing and does not cause significant systemic toxicity both in mouse and nonhuman primates. In summary, this study develops a potential gene therapy strategy for DFNB9 patients in the clinic and provides complete, standardized, and systematic research data for clinical research and application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hearing Loss, SensorineuralHearing LossAdultHumansMiceAnimalsMembrane ProteinsPrimates

Stichwörter der Autor:innen

OTOFgene therapynonhuman primatepreclinical research

Substanzen

Membrane ProteinsOTOF protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Digital Medical Engineering, Department of Otolaryngology Head and Neck Surgery, Zhongda Hospital, School of Life Sciences and Technology, School of Medicine, Advanced Institute for Life and Heal…
  • Co-Innovation Center of Neuroregeneration, Nantong University, Nantong, 226001, China.
  • School of Life Science, Beijing Institute of Technology, Beijing, 100081, China.
  • Department of Neurology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210008, China.
  • Senior Department of Otolaryngology-Head & Neck Surgery, the Sixth Medical Center of Chinese PLA General Hospital, Beijing, 100048, China.
  • Otovia Therapeutics Inc., Suzhou, 215101, China.

ORCID-Profile: Renjie Chai

Förderung

  • National Key Research and Development Program of China
  • STI2030-Major Projects
  • National Natural Science Foundation of China
  • China National Postdoctoral Program for Innovative Talents
  • China Postdoctoral Science Foundation
  • Science and Technology Department of Sichuan Province
  • Shenzhen Science and Technology Program
  • 2022 Open Project Fund of Guangdong Academy of Medical Sciences

Zitieren

APA

Qi, J., Zhang, L., Tan, F., Zhang, Y., Zhou, Y., Zhang, Z., Wang, H., Yu, C., Jiang, L., Liu, J., Chen, T., Wu, L., Zhang, S., Sun, S., Sun, S., Lu, L., Wang, Q., & Chai, R. (2024). Preclinical Efficacy And Safety Evaluation of AAV‐ OTOF in DFNB9 Mouse Model And Nonhuman Primate. Advanced Science, 11(3). https://doi.org/10.1002/advs.202306201

Vancouver

Qi J, Zhang L, Tan F, Zhang Y, Zhou Y, Zhang Z, et al. Preclinical Efficacy And Safety Evaluation of AAV‐ OTOF in DFNB9 Mouse Model And Nonhuman Primate. Advanced Science. 2024;11(3). doi:10.1002/advs.202306201

BibTeX
@article{Qi2024,
  author = {Qi, Jieyu and Zhang, Liyan and Tan, Fangzhi and Zhang, Yang and Zhou, Yinyi and Zhang, Ziyu and Wang, Hongyang and Yu, Chaorong and Jiang, Lulu and Liu, Jiancheng and Chen, Tian and Wu, Lianqiu and Zhang, Shanzhong and Sun, Sijie and Sun, Shan and Lu, Ling and Wang, Qiuju and Chai, Renjie},
  title = {Preclinical Efficacy And Safety Evaluation of AAV‐ OTOF in DFNB9 Mouse Model And Nonhuman Primate},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {3},
  doi = {10.1002/advs.202306201}
}
Kostenlos starten →